The cash inflow associated with the amount received by a corporation from a shareholder during the period.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585

Name:	us-gaap_ProceedsFromContributedCapital
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Collaboration and License Agreements - Joint Venture and License Agreement with Visirna Therapeutics, Inc. - Additional Information (Detail) (Details) - USD ($) $ in Thousands		9 Months Ended
	Apr. 25, 2022	Jun. 30, 2022	Jun. 30, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Proceeds from investment in joint venture		$ 60,000	$ 0
Visirna Therapeutics, Inc. \| Variable Interest Entity, Primary Beneficiary
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Proceeds from investment in joint venture	$ 60,000